Last update June 13, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
8-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride is Buspirone Hydrochloride in Chemical name.
Is written in other languages:8-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride belongs to this group or family:
Main tradenames from several countries containing 8-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Anxiolytic with little sedative action indicated in the treatment of anxiety disorders. Oral administration in two or three daily doses.
In one mother taking buspirone, milk levels were undetectable and plasma levels of buspirone were not detected in the infant. (Brent 1998)
No problems attributable to buspirone have been observed in two infants whose mothers were taking it. (Brent 1998, Newport 2009)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.